Clinical trials and international collaborations
Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study
Merseburger A, et al. Lancet Oncol. 2022
https://www.sciencedirect.com/science/article/pii/S1470204522005605?via%3Dihub
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial
James ND, et al. JNCI Cancer Spectr. 2022
https://academic.oup.com/jncics/article/6/4/pkac043/6649740?login=true
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial
Parker CC, et al. PLoS Med. 2022
https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003998
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476)
James ND, et al. IJC. 2022
https://onlinelibrary.wiley.com/doi/10.1002/ijc.34018
The ReIMAGINE prostate cancer risk study protocol: A prospective cohort study in men with a suspicion of prostate cancer who are referred onto an MRI-based diagnostic pathway with donation of tissue, blood and urine for biomarker analyses
Marsden T, et al. PLoS ONE. 2022
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0259672
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
Attard G, et al. Lancet. 2022
https://www.sciencedirect.com/science/article/pii/S0140673621024375?via%3Dihub
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial
Rush HL, et al. JCO. 2022
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study
Saad F, et al. Lancet Oncol. 2021
https://www.sciencedirect.com/science/article/pii/S1470204521004022?via%3Dihub
Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial
Ali A, et al. JAMA Oncol. 2021
https://jamanetwork.com/journals/jamaoncology/fullarticle/2776418
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.
Clarke N, et al. Ann. Oncol. 2019
https://www.sciencedirect.com/science/article/pii/S0923753420325527
Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate: A Randomized, Open-Label Phase 2 Study.
Attard G, et al. JAMA Oncology. 2019
https://jamanetwork.com/journals/jamaoncology/fullarticle/2737089
Sequencing of agents in castration-resistant prostate cancer.
Lorente D, et al. Lancet Oncol. 2015
https://www.sciencedirect.com/science/article/pii/S1470204515700331?via%3Dihub